Table 1 Clinical characteristics of the patients
| Â | Â | Development n (%) | Validation n (%) | p |
|---|---|---|---|---|
(n = 260) | (n = 132) |  | ||
Age (median, range) |  | 46 (24–78) | 46 (27–72) |  |
Breast Surgery | Breast conserving surgery | 120 (46.2) | 63 (47.7) | 0.768 |
Total mastectomy | 140 (53.8) | 69 (52.3) | Â | |
Axilla Surgery | Sentinel lymph node biopsya | 13 (5.0) | 8 (6.2) | 0.634 |
Axillary lymph node dissection | 247 (95.0) | 122 (93.8) | Â | |
Clinical T stage | T1 | 3 (1.2) | 4 (3.0) | 0.061 |
T2 | 126 (48.5) | 54 (40.9) | Â | |
T3 | 86 (33.1) | 58 (43.9) | Â | |
T4 | 45 (17.3) | 16 (12.1) | Â | |
AJCC Stage | II | 75 (28.8) | 35 (26.5) | 0.627 |
III | 185 (71.2) | 97 (73.5) | Â | |
Histology | Ductal | 237 (91.2) | 121 (91.7) | 0.528 |
Lobular | 6 (2.3) | 5 (3.8) | Â | |
Mixed/other | 17 (6.5) | 6 (4.5) | Â | |
Grade | Low (I and II) | 105 (40.4) | 58 (43.9) | 0.667 |
High (III) | 127 (48.8) | 63 (47.7) | Â | |
Unknown | 28 (10.8) | 11 (8.3) | Â | |
HRc status | Positive | 164 (63.1) | 95 (72.0) | 0.079 |
Negative | 96 (36.9) | 37 (28.0) | Â | |
HER2 status | Positive | 66 (25.4) | 46 (34.8) | 0.072 |
Negative | 193 (74.2) | 86 (65.2) | Â | |
Unknown | 1 (0.4) | 0 (0.0) | Â | |
Subtype | HRc+/HER2- | 131 (50.4) | 69 (52.3) | 0.137 |
HRc+/HER2+ | 33 (12.7) | 26 (19.7) | Â | |
HRc−/HER2+ | 34 (13.1) | 18 (13.6) |  | |
HRc−/HER2- | 61 (23.5) | 19 (14.4) |  | |
Unknown | 1 (0.4) | 0 (0.0) | Â | |
Ki-67 | < 10% | 133 (51.2) | 72 (54.5) | 0.705 |
≥ 10% | 121 (46.5) | 56 (42.4) |  | |
Unknown | 6 (2.3) | 4 (3.0) | Â | |
Type of NST | Anthracyclines | 8 (3.1) | 6 (4.5) | 0.879 |
Anthracyclines and Taxanes | 239 (91.9) | 120 (90.9) | Â | |
Taxanes | 10 (3.8) | 5 (3.8) | Â | |
Others | 3 (1.2) | 1 (0.8) | Â | |
Anti-HER2 Therapy | Neoadjuvant | 12 (4.6) | 6 (4.5) | 0.968 |
Adjuvant | 52 (19.9) | 25 (18.9) | Â | |
No | 196 (75.5) | 101 (76.5) | Â |